



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27890

Title: Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc⁺/Min-FCCC mice

COMMENTS TO AUTHORS

The style is easy-to-read. I suggest to accept the manuscript as it is for publication in WJGPT. Congratulations for the authors!

AUTHORS RESPONSE

Your comments and recommendation are appreciated. The manuscript has been revised as per your suggestion. Please refer the highlighted copy of the revised manuscript to see the changes made to polish the language.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27890

Title: Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc⁺/Min-FCCC mice

COMMENTS TO AUTHORS

I appreciate the author's effort to cover a broad topic. However, at least to me, the presentation of the material appears disorganized. The language is quite simplistic and many of the paragraphs are simply lacking basics. It is entirely inadequate and if published I would not care to read it. This review should be completely rewritten, perhaps narrowing the goals of the review.

AUTHORS RESPONSE

Thank you for your comments. This manuscript is a basic study reporting the chemopreventive potential of plecanatide to delay the onset of inflammation-driven colorectal carcinogenesis in Apc^{Min/+} mice. This manuscript is not a review as we gather from your comments. Nevertheless, we have revised the manuscript to polish the language and make it more organized. Please refer the highlighted copy of the revised manuscript to review changes.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27890

Title: Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc⁺/Min-FCCC mice

COMMENTS TO AUTHORS

Dear authors, I read with great interest the manuscript n. 27890. This manuscript is well written and illustrated, however, I have some remarks: - Since it is a basic study, we need to elucidate the inclusion and exclusion criteria of the studies discussed, together with a flow chart describing such criteria - Tables of the studies analyzing mutation are needed for a wider readability Many Congratulations, Sincerely,

AUTHORS RESPONSE

Thank you for your comments. This manuscript is a basic preclinical study in animal model of inflammation-driven colorectal carcinogenesis in Apc^{Min/+} mice. Thus, this study summarizes *ex-vivo* and *in vivo* animal studies to evaluate the utility of plecanatide in suppressing inflammation-induced colorectal carcinogenesis. Hence there were no inclusion/exclusion criteria. Additionally, the study did not involve mutational analyses and hence no Table(s) has been added to the original manuscript. Nevertheless, we have revised the manuscript to polish the language as suggested. Please refer the highlighted copy of the revised manuscript to review changes.